-
- Dr. Yokoyama joined ReproCELL Inc. in 2004 as a general manager of the business development division and became Chief Executive Officer in 2005. He has been responsible for new product management, alliance, and fund raising, and succeeded in its IPO in 2013. He also participated in establishing a Stem Cell and Drug Discovery Institute in which human ES cell research is carried out for the purpose of drug discovery and toxicity testing applications. From 1996 to 2004, Dr Yokoyama worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, as an R&D leader. He received his Ph.D. in chemistry from the University of Tokyo in 1996.
-
- Mr. Yamakawa has been a non-executive director of ReproCELL since 2008. He is the CEO of HIBIKI Partners, a consulting company, and a BOD member of some listed companies. Having graduated from Waseda University in economics, he started his career as a venture capitalist at Nippon Life Insurance. After experiencing directorship of corporate planning at Innotech Corporation, Mr. Yamakawa joined Sosei Co. Ltd. in 2001 and succeeded in its IPO and M&A as a representative executive officer and CFO.
-
- Mr. Matsubara has served as the Chief Executive Officer since the establishment of Shinsei Corporate Investment in 2012. After graduating from the University of Tokyo in law, he joined the Long Term Credit Bank of Japan (the predecessor of Shinsei Bank), and has experience in retail banking, corporate finance, management of bad loans and trading of Commercial Paper. He has been involved in the Private Equity investment business since 2003 and became the general manager of the Private Equity Division within the Shinsei Bank in 2010. He received his BA in law from the University of Tokyo, and MBA from University of Wisconsin (Madison).
- Mr. Nishimura joined Shinsei Corporate Investment (SCI) in 2013 as a Director, and has been responsible for investment in biotech companies. From 1997 to 2007, he worked for Shinsei Bank as a trader of Commercial Paper and an investment manager of high yield debt, and from 2009 to 2013 for Japanese and European strategy consulting firms (Roland Berger) as a management consultant. He received his BA in economics from the University of Tokyo, and MBA from the Kellogg School of Management, Northwestern University.
